MKC 1
Alternative Names: MKC-1; R 440; RO 31-7453Latest Information Update: 18 Jun 2014
At a glance
- Originator Roche
- Developer CASI Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Hypoxia-inducible factor 1 alpha inhibitors; Importin beta protein inhibitors; Mitosis inhibitors; MTOR protein inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Breast cancer; Haematological malignancies; Leukaemia; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
- 10 Nov 2008 MKC 1 meets primary efficacy endpoint in open-label phase I/II study in non-small cell lung cancer
- 03 Jun 2008 Interim efficacy and adverse events data from a phase I/II trial in advanced Non-small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)